spacer
home > ebr > winter 2009 > targeting tumours
PUBLICATIONS
European Biopharmaceutical Review

Targeting Tumours

With existing monoclonal antibody drugs for the treatment of cancer having achieved blockbuster status, what further benefits can antibodies bring to the field of cancer therapeutics? For example, can the success of the anti-angiogenic Avastin® (bevacizumab, Roche) be equalled or bettered? The potential of targeting alternative or additional proteins involved in generating new blood vessels has been recognised; a deal has been secured around an antibody in development that binds placental growth factor (PlGF). Other treatment strategies in which antibodies are used to inhibit protein kinase function or induce cell death are also being developed.

THE ESTABLISHMENT OF mAbs

It is now over 10 years since the first monoclonal antibody (mAb) drug was launched onto the market to treat cancer. Since then, the market for this class of drugs has grown rapidly, driving new growth in the cancer and pharmaceutical market as a whole. In 2006, four of the top 10 innovative cancer treatments were monoclonal antibodies: Rituxan/ MabThera (rituximab), Herceptin (trastuzumab), Avastin (bevacizumab) and Erbitux (cetuximab). Together, these treatments achieved sales figures in excess of $10 billion (1).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Mats Hellström is a Senior Principal Scientist at BioInvent International and is responsible for preclinical research in the areas of angiogenesis, stroma biology and oncology. Prior to joining BioInvent, Mats was CEO of the drug discovery company, AngioGenetics AB. He has been a researcher at the Karolinska Institutet and has a PhD from Gцteborg University, Sweden.

Björn Frendéus is a Senior Principal Scientist at BioInvent International, responsible for preclinical research in the areas of inflammation and immunology and is also involved in target discovery. Before joining BioInvent, Bjцrn was a researcher at the Department of Clinical Immunology at Lund University in Sweden where he earned his PhD.

spacer
Mats Hellström
spacer
spacer
spacer
Björn Frendéus
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ACG: “The global pharmaceutical solutions company on a mission to help manufacturers keep their supply chains moving”


More info >>

White Papers

Wrap Around Label - A Lot of Content in a Small Space

Faubel & Co. Nachfolger GmbH

One of the world’s largest contract research organizations for the planning and conducting of clinical trials was faced with the challenge of accommodating many different national languages on an inhaler. The inhaler was then to be distributed in 47 countries. Due to the impressive quality and reliable collaboration, the organization commissioned Faubel with finding the optimal labeling solution for the inhaler.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement